TD-1792 in Gram-positive Complicated Skin and Skin Structure Infection

Completed · Phase 2

Conditions studied: Staphylococcal Skin Infection

In brief

The purpose of this study is to determine whether TD-1792 is safe and effective when used to treat complicated skin and skin structure infections caused by Gram-positive bacteria.

Key facts

Study ID

NCT00442832

Run by

Theravance Biopharma

People needed

203

Starts

2006-12-01

Expected to finish

2007-05-01

Last updated by the study team

2021-01-20

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• major abscess requiring surgical incision and drainage,infected burn, deep/extensive cellulitis, infected ulcer, wound infections
• requires at least 7 days of intravenous antibiotic treatment

You may not qualify if…

• more than 24 hours of antibiotic therapy
• moderate or severe liver disease
• severely neutropenic
• baseline QTc > 500 msec, congenital long QT syndrome, uncompensated heart failure, uncorrected abnormal K+ or Mg++ blood levels or severe left ventricular hypertrophy

Where it is running

• Allan Churukian — National City, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.